Cost Analysis and Rational Use of Anti Glaucoma Therapy in A Tertiary Hospital in Ghana

CHARLES NII KWADE OFI-PALM (✉ c.ofei-palm@kbth.gov.gh)
KBTH: Korle Bu Teaching Hospital

NAA Naamuah Tagoe
KBTH: Korle Bu Teaching Hospital

DANIEL NII AMOO ANKRAH
KBTH: Korle Bu Teaching Hospital

Dong Jatoe
PHARMACY UNIT, LIONS INTERNATIONAL EYE CENTRE, KORLE BU TEACHING HOSPITAL GHANA

Angela Agyare
PHARMACY UNIT, LIONS INTERNATIONAL EYE CENTRE, KORLE BU TEACHING HOSPITAL GHANA

Research Article

Keywords: Cost analysis, Anti glaucoma therapy, rational drug use, Korle bu, Ghana

DOI: https://doi.org/10.21203/rs.3.rs-284227/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction

Glaucoma is the leading cause of irreversible blindness worldwide. In Ghana, 19.4% of all blindness recorded is due to glaucoma. Reducing intraocular pressure medically (using eye drops) is the evidence-based therapeutic option

Objectives

To determine the rational use and undertake cost analysis of anti-glaucoma drugs among patients attending clinic at the Lions International Eye Centre, Korle bu Teaching Hospital (LIEC).

Methods

In this cross sectional study, we reviewed all prescriptions presented to the pharmacy unit from 01/12/015 to 31/03/2016. The dispensed drops were classified and all anti-glaucoma drugs were identified. This was followed by cost analysis.

Results

A total of 588 prescriptions were captured, 27.3% (161/588) contained an anti-glaucoma medication. The mean number of anti-glaucoma medications was 1.71 of which 52.7% was prescribed to females. Prostaglandin analogues were the most prescribed (37% (102/276)), followed by beta blockers (25.4% (70/276)), carbonic anhydrase group of medicines (16.3% (45/276)), combined beta blockers (11.2% (31/276)), alpha agonists (8.7% (24/276)) and miotics (1.4% (4/276)). The median (IQR) average cost of anti-glaucoma therapy per prescription per month was GHC 65.00 (GHC38.5-GHC140). Azopt (Brimonidine) was the most expensive with daily treatment cost of GHC 5.8 (about US$ 1.45), whilst the least expensive drug with a daily treatment cost of GHC 0.14 (about US$ 0.035) was timolol eye drops.

Conclusions

Prostaglandins analogues remain the most preferred treatment for managing glaucoma at the Korle-Bu Eye Centre in Ghana but are also the most costly. This may adversely affect treatment among the poor since prostaglandins are currently not reimbursed.

Introduction

Glaucoma is the leading cause of irreversible blindness worldwide. Glaucoma, however, presents an even greater public health challenge than cataracts: because it causes irreversible blindness [1].

Currently, it is estimated that 80 million people in the world live with Open Angle Glaucoma (OAG) and Angle Closure Glaucoma (ACG) glaucoma of which 11 million are blind. This prevalence is an increase of about 20 million since 2010. Fifty-five percent of women have OAG, 70% of ACG, and 59% of all glaucoma in 2010 [2].

Most glaucoma in Africa is primary open angle glaucoma, which occurs at an earlier age, associated with a higher intraocular pressure, more rapidly progressive and late presentation [3].
Efforts to understand more about the magnitude and distribution of glaucoma in Africa have usually been limited by reliance on clinic populations and inadequate definitions of glaucoma. Nonetheless, the surveys indicate that OAG is an important cause of blindness in Africa. The early stages of both types of glaucoma are often asymptomatic so patients often present late, particularly in developing countries [4, 5, 6, 7, 8].

The challenges are with late presentation for diverse reasons one of which is low awareness and the silent nature of the disease [4, 5, 7]. Reports indicate that at least half of eyes are already blind at presentation [9].

In Ghana, 19.4% of blindness is due to glaucoma. The prevalence of blindness and severe visual impairment was 0.74% and 1.07% respectively whilst in rural Ghana, one third (34.1%) of all glaucoma patients report bilaterally blind while half are uniocularly blind [7].

At present, there are no therapies available that prevent the development of glaucoma. Similarly, no therapies are available to reverse glaucoma-induced vision loss. However, a reduction of the intraocular pressure (IOP) has been shown to protect against further damage to the optic nerve head [10]. Reducing IOP is presently the evidence-based, most accepted, and most practised therapeutical approach of glaucoma patients [11]. Results of key landmark trials have shown that lowering intraocular pressure is the mainstay of management [12, 13, 14, 15, 16].

Innovations in diagnosis and therapy has made glaucoma management complex. Though surgical options are available for lowering of intraocular pressure, medication remains the first line in most cases of glaucoma [17].

Drug management of glaucoma commonly includes six classes of drugs: α-adrenergic agonists, β-adrenergic antagonists, cholinergic agonists, prostaglandin analogues, carbonic anhydrase inhibitors and a combination of these groups.

In most developing countries like Ghana, most clients don't have the money to pay for the eye drops which they may need to take for the rest of their lives [18].

The therapy for the glaucoma is now in a dynamic phase, and management of the disease has an enormous impact on our society in terms of patient's morbidity, loss of productivity, number of ophthalmic consultations and health care costs, as these patients may have to continue the therapy for the rest of their lives once diagnosed with the disease.

As newer pharmacological agents and other treatment modalities become available; Ophthalmologists may have a dilemma choosing a low cost but effective anti-glaucoma medication from the wide variety of options available.

In spite of all these, very few studies have been done in Ghana to look at the cost analysis of glaucoma therapy in general to provide patients and health care providers with calculated yearly costs of topical glaucoma medications.

We therefore conducted this study to determine the rational use and undertake cost analysis of anti-glaucoma drugs among patients attending clinic at the Lions International Eye Centre (LIEC) of the Korle bu Teaching hospital and to provide patients and healthcare providers with calculated yearly costs of topical Anti glaucoma medications prescribed.

Methodology
This was a cross-sectional study at LIEC, Korle Bu Teaching Hospital based on adherence to the standard prescription form at the hospital. As a routine, all prescriptions submitted and dispensed at the pharmacy are detained. We reviewed prescriptions that were presented to the pharmacy unit from 1st October 2015 to 31st March 2016. All prescriptions that had at least one medicine served were captured at the unit. Medicines that were not available or dispensed (due to non-affordability of patients) were not captured as patients took those prescriptions away. A copy of the prescription was obtained with the help of a pre-inserted carbon, in a special format. A copy of the prescription was kept at the pharmacy unit together with a copy of the point of sales receipt which generates the names and cost of drugs purchased. Two (2) members of staff were trained to extract Data from the prescription forms. A Specialist Pharmacist and a Pharmacy Technologist reviewed the classifications of all the medicines on the prescriptions captured.

All the prescriptions were analyzed for the type of the anti-glaucoma medication prescribed, percentage of mono-therapy vs. combination therapy prescribed, percentage of fixed dose combination prescribed, percentage medicines prescribed using generic names and cost analysis (monthly and yearly) for all the types of anti-glaucoma drugs including their dose, frequency, duration and route of administration. Each parameter was expressed as a percentage.

Cost analysis of different anti-glaucoma medication

The average cost per ml of different drugs (eye drops) was determined by calculating cost per ml of the various brands. As size of a drop is between 25 to 50 ul, an average of about 27 drops constitute 1 ml. For drugs used in both eyes, we calculated the number of drops required per day (determined by using the manufacturer’s recommended daily dosing regimen) for each medication, and then we calculated the cost of therapy for a month and a year.

Data extracted was entered into Microsoft Excel and subsequently exported into SPSS Version 20 for analysis. Descriptive statistics of patients’ demographics and types of prescribed anti-glaucoma medications were presented as counts and proportions. Chi-square test was used to analyze the data where appropriate and values with P < 0.05 were considered statistically significant.

ETHICAL STATEMENT

In this study no patients were contacted. Collection of prescriptions of patients is a routine process in the hospital. In doing the study all identifiable information of patients were de-identified from prescription. The threat to patients was therefore minimal and did not need the approval of an Ethics Committee.

Results

A total number of 588 prescriptions were captured in the study because of the availability of the duplicate carbon prescription forms. Out of this number of prescriptions, 161 (27.3%) contained an anti-glaucoma medication. The total number of anti-glaucoma drugs in the 161 prescriptions was 276 with an average of 1.71 (about 2) per prescription.

Of 161 patients, 85(52.7%) were prescribed to female clients and 76 (47.2%) to male clients Mean age was 58.6±21.2 years with information on the ages not available for 68.7% of prescriptions captured.
Prostaglandin analogues (PGA) were the most prescribed (102/276(37%)) medicines, followed by beta blockers (BB) (70/276 (25.4%)), with the Miotics (CM) (4/276 (1.4%)) being the least prescribed. See Figure 1.

Latanoprost was the most prescribed (93/102 (91.2%)) among the prostaglandin analogue group with bimatoprost (Lumigan) (4/102 /3.9%)) being the least prescribed. See Figure 2

Timolol was the most prescribed (56/70 (80%)) beta blocker followed by levobunolol (Betagan) (8/70 (11.4%)) and bexalol (Betoptic) (6/70 /8.6%) in that order. See Figure 3

Oral acetazolamide accounted for 72.3% (34/45) within the carbonic anhydrase group followed by brinzolamide (Azopt) (27.7% (13/45)).

With the combined beta blockers, Timolol+ brinimodine (Combigan) accounted for 64.5%, whilst Timolol + dorsolamide and Timolol+ Bimatoprost represented 32.3% and 3.2% respectively.

Combination therapy or fixed dose combination therapy (FDC) constituted 55.1% of prescriptions whilst monotherapy was 44.9%. Latanoprost was the most prescribed representing 45.2% of all the monotherapy treatment in the study, followed by timolol which recorded 17.3%. See Figure 4

Anti-glaucoma therapy prescribed as generics were 141(51.1%) and proprietary brands accounted for 135 (48.9%).

The median (IQR) cost of anti-glaucoma therapy per prescription per month was GHC 65.00 (GHC38.5-GHC140).

Cost analysis

Branded travoprost (Travatan) was the most expensive treatment amongst the prostaglandins with a daily treatment cost of GHC 4.90 (about US$1.20), followed closely by branded latanoprost (Xalatan) with a daily treatment cost of GHC 3.60 (about US$0.90). However, the generic latanoprost is about half the treatment cost of the branded counterpart. The least expensive drug with a daily treatment cost of GHC 0.14 (about US$ 0.035) was timolol eye drops whilst Brinzolamide (Azopt) was the most expensive with a daily treatment of GHC 5.80 (about US$1.45)

The median (IQR) cost of anti-glaucoma therapy per prescription per month was GHC 65.00 (GHC38.5-GHC140) about [US$16.25 (US$ 9.6 – US$35)] See Table 1

Discussion

This study sought to analyze the costs and prescription patterns of anti-glaucoma medicines used in a tertiary hospital in Ghana, a Sub Saharan African (SSA) country. The strength of our study lies in the fact that to the best of our knowledge, there are no published data to review on the drug utilization and cost analysis of anti-glaucoma medications in the ophthalmic department of a tertiary teaching hospital in Africa in general and Ghana in particular

In our study the total number of drugs in the 161 prescriptions was 276. The average number of drugs/prescriptions was 1.71 (~2). This is well within the WHO recommended limit of 2 [19] and falls within the rational use of drugs requirement as stipulated by the WHO. This recommended limit criteria set out by the WHO is an important tool for assessing rationality of prescriptions [20]. Our results are comparable to other studies that had similar averages.
but higher in a study reported in India that reported average of 1.49 per prescription [23] but lower averages compared to the other similar studies [24, 25, 26, 27, 28, 29].

An increase in the number of average drugs per prescription is an important index used to measure an indication for polypharmacy which is associated with an increased risk of drug interactions. This may further lead to unwanted side effects and may also increase prescribing and dispensing errors.

Even though sex did not play any role in glaucoma as illustrated in these studies [2, 30], in our study there were more prescriptions given to female (52.7%) than male (47.2%) clients. Similar result was reported in another study in Ghana [31] and other studies in India [32, 33]. This calls for further and most probably larger studies to ascertain the role played by gender among Ghanaian patients with glaucoma.

Drug management of glaucoma commonly includes six classes of drugs: α-adrenergic agonists, β-adrenergic antagonists, cholinergic agonists, prostaglandin analogs and carbonic anhydrase inhibitors and a combination of these groups [34]. In our study, Prostaglandin analogues were the most prescribed anti glaucoma medicine representing 37% of all the anti-glaucoma medications within this group, with latanoprost as the most prescribed prostaglandin Beta blockers represented 25.4% of the total category of anti-glaucoma medicines prescribed in the study. Amongst the beta blockers, timolol was the most prescribed representing 80% of the total number of beta blockers found in the study.

This is in line with other published literature concerning the use of prostaglandins analogues as a first line of choice in the treatment of glaucoma [35, 36, 37, 38] but in contrast to other studies that were carried out in India where beta blockers most especially timolol was most used [39, 40, 41 42]. The reasons we attribute to the PGA usage as a first line of choice is that it is the drug of choice recommended by Ghana Standard Treatment Guidelines [43] for the treatment of Glaucoma in Ghana, it is also part of the Ghana Essential Drug List [44] but unfortunately not included in the list of drugs of the National Health Insurance List (NHIA) [45] which is the list most patients receiving those drugs could have afforded. A look at the cost analysis proved that prostaglandins were far more expensive than beta blockers. This is an indication that all those patients with a prostaglandin prescription will have to pay out of pockets to get their medication. This will create lots of economic constraints to clients especially those with low socio-economic status. It may even lead to non-adherence to treatment which may have a profound effect on treatment prognosis.

Prostaglandin analogues have superseded beta adrenergic blockers as the primary mode of treatment for primary open angle glaucoma because of better patient compliance (it is used once a day whilst other drops are used 2-3 times daily) and lesser adverse effect [46, 47]. Furthermore, Prostaglandin analogues compared to β-blockers have greater efficacy in lowering diurnal and nocturnal IOP with lesser systemic adverse effects [48, 49].

With the carbonic anhydrases, apart from it being the third most prescribed medicine, it is the only group with an oral preparation. Oral acetazolamide accounted for 72.3% of the total number prescribed from this group and brinzolamide (Azopt) accounted for only 27.7%.

It is not surprising to see acetazolamide as the only used oral anti-glaucoma. Topical drugs have proved far effective than oral medications. The rationale for the preference of topical over oral is to minimize systemic side effects. It is a routine practice in this hospital to prescribe oral acetazolamide for a day to a week to three months and then discontinue and replace it with other topical drug if necessary. The rationale given by prescribers is to lower cost. Acetazolamide is prescribed a lot because it is affordable and covered under National Health Insurance
Scheme. Most of the patients put on it cannot afford prostaglandins analogues so despite its side effects it still remains useful. It also attains faster reduction of IOP. It is used for short period of time so that chance of acidosis and other side effects like bone marrow depression and renal stone, gastro intestinal disturbances, tinnitus and hypokalemia could be minimized [42].

In our study, topical carbonic anhydrase inhibitor Brinzolamide was prescribed in (4.0%) of the patient. It was prescribed less frequently as mono therapy possibly because of higher frequency of instillation required (3 times a day) compared to prostaglandin analogs which are instilled once at night and β-blockers mainly timolol prescribed for instillation 2 times daily. It also has higher cost as compared to prostaglandin analogs and β-blockers. These factors are important in considering the compliance in patients with glaucoma which plays an important role in control and prevention of progression of the disease hence its lower usage in the study.

Prescriptions for combination therapy were more prevalent compared to prescriptions for monotherapy. This is in line with other studies that indicated that combined therapy yields additive and better results than monotherapy in higher intra ocular pressure (IOP) reduction. [50]. However, combination therapy is given only when the patient requires more than one anti-glaucoma medication. Combination therapy can be with fixed drug combinations (FDC) or concurrent use of more than one anti-glaucoma medication. Most FDC contains a beta blocker. FDC therapy leads to improved compliance and enhance patient convenience, compliance, cost effectiveness and safety. [51] Our result is comparable to other studies. [42, 40] but demonstrated higher usage compared to other study which didn't report on usage of FDC therapies [39].

In our study FDC with beta blockers accounted for 11.2% of the medications for the study. Timolol + brimonidine (combigan) mainly prescribed as a proprietary or branded drug accounted for 64.5% of the study. Apart from lowering the IOP, brimonidine also has neuro protective effect [52] and also constituted to 8.7% of anti-glaucoma medications in this study. This might have contributed to the prescribers’ choice even though it is expensive. This is in line with other studies that suggested the same drug as the most frequently prescribed FDC [42] other studies have reported timolol plus dorsolamide [40] and timolol plus Bimatoprost [53] as the most used FDC even though in our study they were second and third most frequently used FDC respectively.

Timolol remained the most used beta blocker accounting for 80% of usage in our study. This could be attributed to its low cost of GHC 0.14 per day as well as coverage under National Health Insurance Scheme. This prescription pattern is corroborated by other studies in which it was reported as the frequently prescribed drug [54].

Similar patterns regarding beta-blocker usage have been reported [42, 39].

Only 1.4% patients were put on miotics or para-sympathomimetic in our study, these were class of drugs that are not preferred now for the management of glaucoma because of the commonly associated side-effects like diminished night vision, reduced visual acuity, opacities, myopia and visual field contraction hence its low patronage by prescribers [39] and very few studies reported its usage [31]. There is clear indication of its usage gradually diminishing in the treatment of glaucoma as indicated in our study.

Many drugs were prescribed by generic names (51.1%) in our study. Prescribing under generic name is considered economical and rational. The World Health Organization strongly advocates the practice of prescribing drugs by their generic names [55]. The World Health Organization advocates use of only generic names from national essential medicines list (NEML) for better management [56]. This study also revealed that the percentage of drugs
prescribed from Ghana National Essential Drug List was very high almost 100%. The exception are the fixed dose combination therapies.

In our study topical prostaglandins have become a common first-choice glaucoma therapy, partly owing to their relatively consistent clinical efficacy, and also due to their lower frequency of adverse effects. However, topical prostaglandin analogs are expensive, ranging from generic GHC1.18 = US$0.26 to GhC1.93 =US$0.42 per day and branded prostaglandin ranged from GHC3.6 = US$0.80 to GHC4.9 =US$1.10 per day. The least expensive option for the medical therapy of glaucoma was generic timolol products. This study showed an average cost of GHC0.20 = US$0.04 per day compared to the branded timolol (Cusimolol-Alcon) with an average daily cost of GHC0.59 = US$0.13.

Concerning the fact that Ghana is a developing country our cost per day is far lower than what is reported in the western world even as compared to the same branded product [57].

For example branded prostaglandin (Xalatan) that cost US$0.8 in our study, costs US$1.25 in the USA [57]. In our study, the cost per year for branded brimonidine (Alphagan,) and branded brinzolamide (Azopt) were US$223 and US$527 respectively but in a study conducted in the USA that evaluated yearly cost of glaucoma medications at a University-affiliated teaching hospital with its own health maintenance organization for a three year period (1998 to 2000), the cost of branded brinzolamide (Azopt) was about half. [58]. This high cost makes the drug very unlikely to be prescribed by ophthalmologists in our setting even though it is a good option.

Finally our study showed that the highest cost of glaucoma treatment per prescription per annum is US$ 420. This is similar to a study done in Ghana [31] that looked amongst other things at the cost of glaucoma medications.

Our Prices were obtained from the hospital based government facility where prices are heavily subsidized or reduced because of competitive tender processes and also low mark up as compared to private pharmacies and private hospitals where the average cost is likely to be higher.

Prostaglandins remain the most preferred treatment for managing glaucoma by prescribers at the Lions International Eye Centre of the Korle bu Teaching Hospital but are also the most costly followed by Beta blockers. This is in line with Western world literature that chooses prostaglandin analogue over beta blockers [35, 36, 37, 38]. This outcome is also in line with standard treatment guidelines in Ghana but may adversely affect treatment among the poor since prostaglandins are currently not reimbursed in the national health insurance scheme.

The Mean age was 58.6±21.2 years with 68.7% information on the ages not available. This percentage of missing values for the age made it difficult for us to compare our study with other age groups in other studies but this is quite similar to the prevalence study that was done at Tema in Ghana [59].

The study did not account for patients or clients who presented prescriptions to the pharmacy but did not purchase the prescribed drug as well as those who presented prescriptions but could not be served due to unavailability of the drops at the pharmacy. Such clients would usually take their prescriptions away.

These findings cannot be generalized as prescribing preferences may vary from one hospital to another in the absence of a national treatment guideline for glaucoma diseases. However, being a national training centre for most ophthalmologists in Ghana, the results may be a true representation of prescribing pattern for glaucoma medication in Ghana.
Further, the study did not provide the type of glaucoma treated as this was not available on the prescription.

**Conclusion**

The average cost of anti-glaucoma therapy provided by this study is a guide for patients and prescribers on how much is spent annually on the management of ophthalmic morbidities.

For glaucoma whatever therapy is chosen, the concept to be kept in mind is that therapy is lifelong and needs consideration of cost-effectiveness and convenience in individual patients in order to avoid irreversible blindness that could lead to lack of productivity or adversely affect productivity.

In presence of wide cost variation among various brands of the same drug our study could help the ophthalmologist to use all possible measures of pharmacoeconomics while prescribing an anti-glaucoma drug. We estimated in this study that each glaucoma patient will spend approximately between GHC 462 to GHC 1680 per annum.

**Recommendation**

Since PGAs were the most prescribed yet not covered by National Health Insurance Scheme, we recommend that it be considered for inclusion in the list of drugs to be used to treat glaucoma since it is also already captured in the Essential Drug List and the Ghana Standard Treatment Guidelines to make PGAs more accessible for the poor.

**Declarations**

- **Funding /support:** this paper received no funding/not applicable
- **Conflicts of interest /competing interests:** none/not applicable
- **Availability of data and material:** not applicable
- **code availability:** not applicable
- **ethics approval:** did not need the approval of an Ethics Committee:-no threat to patients
- **consent to participate:** not applicable
- **consent for publications:** all authors have consented to publish in IJCP

**References**

1. Kutty, GKV., Sambasivam, N., Nagarajan, M. *A study on: drug prescribing pattern in Madurai city*. Ind J Pharmacol 2002; 34(5):361-362.

2. Quigley, HA., Broman, AT. *The number of people with glaucoma worldwide in 2010 and 2020*. British Journal of Ophthalmology 2006; 90(3):262-267.

3. Cook, C. *Glaucoma in Africa: Size of the problem and possible solutions*. J Glaucoma. 2009;18(2):124–8

4. Cook, C., Foster, P. *Epidemiology of glaucoma: What's new?*. Can J Ophthalmol. Elsevier, 2012;47(3):223–226
5. Kyari, F., Abdull, MM., Bastawrous, A., Gilbert CE. Et al. Epidemiology of glaucoma in sub-saharan Africa: prevalence, incidence and risk factors. Middle East Afr J Ophthalmol. 2013;20(2):111–1125

6. Ntim-Amponsah, CT., Amoaku, WMK., Ofosu-Amaah, S. et al. Prevalence of glaucoma in an African population. Eye (Lond). 2004;18(5):491–497.

7. Gyasi, MK., Amoako, M. Presentation patterns of primary open angle glaucomas in North eastern Ghana. Ghana Medical journal 2010;1(44):25-30

8. Resnikoff, S., Foster, A. The impact of Vision 2020 on global blindness. Eye (Lond). 2005;19(10):1133–1135

9. Lewallen, S., Courtright, P. Blindness in Africa: present situation and future needs. British Journal of Ophthalmology2001;85(8):897-903.

10. Schulzer, M., Drance, SM,, Douglas, GR. A comparison of treated and untreated glaucoma suspects. Ophthalmology. 1991;98(3):301–307.

11. Shaarawy,T., Flammer, J., Haeiger IO. Reducing intraocular pressure: Is surgery better than drugs? Eye. 2004;18(12):1215–24.

12. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol2000; 130(4):429–440

13. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126(4):498–505.

14. Gordon MO, Beiser IA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol2002;120(6):714–20

15. Ianz NK, Wren PA, Lichter PR et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 2001;108(11):1954–1965

16. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol2002;120(6):701–713

17. RP L. A Canadian glaucoma strategy. Can J Ophthalmol. 2007;42(2):60–65

18. Egbert PR. Glaucoma in West Africa: a neglected problem. Br J Ophthalmol. 2002;86(2):131–132.

19. W How to investigate drug use in health facilities: Selected drug use indicators. Geneva: World Health Organization. WHO/DAP 1993; 1:1-87

20. Banerjee, I., Bhadury, T., Sengupta, T. et al. Drug Utilization Study in Ophthalmology Out-patient Department of a Medical College in India. Ann Med Health Sci Res 2014; (4):667– 670

21. Parween, N., Gupta, S., Kumar, S. et al. Drug Utilization Study In Primary Glaucoma Patients Attending Ophthalmology Outpatient Department of a Tertiary Care Hospital of Western Uttar PradeshDelhi J Ophthalmol 2017;28(1):25-29; Doi: http://dx.doi.org/10.7869/djo.286

22. Mahajan, HM., Honrao, R., Borkar, AS. et al. A Drug Utilization Study in Glaucoma Patients in a Tertiary Care Hospital of Central. Indian J Cont Med 2015; 3(2):44-47

23. Pradeep, RJ., Vijay, VM., Yeshwant, AD. Drug Utilization Study in Ophthalmology Outpatients at a Tertiary Care Teaching Hospital. ISRN pharmacology. 2013. 768792. 10.1155/2013/768792.

24. Biswas, NR., Biswas, et al. Patterns of prescriptions and drug use in two tertiary hospitals in Delhi, Indian Journal of Physiology and Pharmacology. 2000;44(1) 109–112,
25. Biswas, NR., Jindal, S., Mairaj, S. et al. **Patterns of prescription and drug use in ophthalmology in a tertiary hospital in Delhi**, *British Journal of Clinical Pharmacology*. 2001;51(3):267–269.

26. Singh, J., Biswas, NR., Jain, SK. et al. **Prescribing trends in ophthalmology**, *The Indian Journal of Clinical Pharmacology and Therapeutics*. 1998;18(4):79

27. Maniayar, Y., Bhixavatimath, P., Akkone, V. **Drug utilization study in the ophthalmology department of a medical college, Kamataka, India**, *Journal of Clinical and Diagnostic Research*. 2001;5(1):82–84

28. Nehru, M., Kohli, K., Kapoor, B., et al. **Drug utilization study in outpatient ophthalmology department of Government Medical College Jammu**, *JK Science*. 2005;7(3):149–151.

29. Jain, VP., Shrivastava, B., Agarwal, M. **Drug utilization pattern of drugs used along ophthalmic antiallergics formulations used in patients diagnosed with seasonal and perennial allergic conjunctivitis**, *Asian Journal of Pharmaceutical Sciences and Research*. 2011;1(5):15–20.

30. Klein, BE., Klein, R., Sponsel, WE. **Prevalence of glaucoma. The Beaver Dam Eye Study**, *Ophthalmology*. 1992;99(10):1499–504.

31. Ocansey, Kyei, S., Diafo, A. **Cost of medical management and prescription pattern for primary open angle Glaucoma (POAG) in Ghana- a retrospective cross sectional study from three referral facilities**, *BMC Health Serv. Res*. 2016: 2016(16):1-8

32. Yadav, AK., Patel, V. **Drug use in primary open angle glaucoma: A prospective study at a tertiary care teaching hospital**, *Indian J Pharmacol*. 2013;45(2):117-120

33. George, R., Ve, RS., Vijaya, L. **Glaucoma in India: Estimated burden of disease**, *J Glaucoma*. 2010;19(6):391-397.

34. Alward, WL. **Medical management of glaucoma**, *N Engl J Med*. 1998;29(18):1298–1307

35. Carroll, SC., Gaskin, BJ., Goldberg, I. et al. **Glaucoma prescribing trends in Australia and New Zealand**, *Clin Experiment Ophthalmol*. 2006;34(3):213-218.

36. Kashiwagi, K. **Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community**, *Open Ophthalmol J*. 2010;4:7-11

37. Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee; Canadian Ophthalmological Society. **Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye**, *Can J Ophthalmol*. 2009;44(1):S7-93

38. American Academy of Ophthalmology, Glaucoma Panel. **Preferred Practice Pattern® Guidelines. Primary Open-Angle Glaucoma. San Francisco**, CA: *American Academy of Ophthalmology*, 2010 Available from: http://www.aao.org/ppp. [accessed on 16 February 2019]

39. Sharma, R., Khajuria, R., Sharma, P. et al. **Glaucoma therapy: Prescribing pattern and cost analysis**, *JK Science*. 2004; 6(2):88-92.

40. Yadav, AK., Patel, V. **Drug use in primary open angle glaucoma: A prospective study at a tertiary care teaching hospital**, *Indian J Pharmacol*. 2013;45(2):117-120

41. Carroll, SC., Gaskin, BJ., Goldberg, I. et al. **Glaucoma prescribing trends in Australia and New Zealand**, *Clin Experiment Ophthalmol*. 2006;34(3):213-218.

42. Rai, S., Khilji, S., Rao, LG. et al. **Prescribing pattern and adverse events of drugs used in patients with primary open-angle glaucoma (POAG) attending a tertiary care hospital: Retrospective study**, *Natl J Physiol Pharm Pharmacol*. 2017;7(2):189-193
43. Standard Treatment Guidelines 2018. Ministry of Health, Ghana. moh.gov.gh/wp-content/uploads/.../Standard-Treatment-Guideline-2010.pdf. [Accessed 16th February 2019].

44. Essential medicines list 2017. Ministry of Health, Ghana. http://apps.who.int/medicinedocs/documents/s18014en/s18014en.pdf. [Accessed 16th February 2019].

45. National Health insurance list. nhis.gov.gh/nhia.aspx. Accessed 16th February 2018.

46. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs. 2000;59(3):411–434.

47. Stewart, WC., Konstas, AG., Nelson, LA. et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008; 115(7):1117– 1122.

48. Liu, JH., Medeiros, FA., Slight, JR. et al. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology. 2009;116(3):449-454.

49. Carlsson, AM., Chauhan, BC., Lee, AA. et al. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension. Am J Ophthalmol. 2000;129(6):297-301.

50. Dutta, LC., Maskati, BT., Dutta, KK. Current trends in drug therapy of POAG. In: Dutta LC, editor. Modern Ophthalmology. 2000; 1. 481-487.

51. Kulkarni, SV., Damji, KF., Buys, YM. Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency. Patient Prefer Adherence. 2008;2:303-314.

52. Schuman, S.J., Burke, J., Cantor, BL.et al. Innovations in the medical management of glaucoma. Oxford institute for continuing Education, 2000.

53. Ahmed, QS., Sayedda, K., Agarwal, A et al. Drug utilization study of antiglaucoma drugs in a tertiary care teaching hospital, Bareilly. World Journal of Pharmaceutical Research 2014; 3:2420- 2428.

54. Stephen, CG., Mark, J., Alan, LR et al. Clinical pharmacology of adrenergic drugs. In: Ritch R, Bruce MS, Theodore K, editors. The Glaucomas, Glaucoma therapy, 2nd ed., vol 3. St. Louis, MO: Mosby-Year Book, Inc; 1996. p. 1425-1446.

55. Action program on essential drugs - Action for equality; WHO/DAP/92.5.

56. World Health Organization. How to investigate drug use in health facilities: selected drug use indicators. 1993. http://apps.who.int/medicinedocs/en/d/Js2289e/. Accessed July 18 2020.

57. Fiscella, RG., Green, A., Patuszynski, DH. et al. Medical therapy cost considerations for glaucoma. Am J Ophthalmol. 2003;136(1):18–25.

58. Vold, SD., Riggs, WL., Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma. 2002 Aug; 11 (4):354-8.

59. Budenz, DL., Barton, K., Whiteside-de Vos, J. et al. Prevalence of glaucoma in an urban West African population: the Tema Eye Survey. JAMA Ophthalmol. 2013;131(5):651-8.

Tables
| Type of various Anti-Glaucoma Therapy (Generic/proprietary) | Concentration | millimeters/ml | cost /bottle GHC | Cost /ml GHC | Dose/day Both Eyes (Drops) | Cost/Day GHC | Cost/Month GHC |
|----------------------------------------------------------|--------------|---------------|------------------|--------------|----------------------------|--------------|----------------|
| Latanoprost-Proxinol                                     | 0.5%         | 2.5mls        | 40               | 16           | 2                          | 1.18         | 35.5           |
| Latanoprost-Texop                                         | 0.5%         | 2.5mls        | 65               | 26           | 2                          | 1.93         | 57.7           |
| Latanoprost-Xalatan                                       | 0.5%         | 2.5mls        | 130              | 52           | 2                          | 3.6          | 115.6          |
| Bimatoprost-Lumigan                                       | 0.3%         | 3mls          | 103              | 34.3         | 2                          | 3.05         | 91.6           |
| Timolol- UK Brand                                         | 0.5%         | 5mls          | 5                | 1            | 4                          | 0.14         | 4.5            |
| Timolol- Cusimolol                                        | 0.5%         | 5mls          | 20               | 4            | 4                          | 0.59         | 17.8           |
| Timolol-Epitimol                                          | 0.5%         | 5mls          | 12               | 2.4          | 4                          | 0.36         | 10.7           |
| Levobunolol-Betagan                                       | 0.5%         | 5mls          | 18.5             | 3.7          | 4                          | 0.54         | 16.4           |
| Timolol + Brinomidine (COMBIGAN)                          | -            | 5ml           | 89               | 17.8         | 4                          | 2.6          | 79.1           |
| Timolol + Dorzolamide (EPISOPT)                           | -            | 5ml           | 66               | 13.2         | 4                          | 1.96         | 58.7           |
| Travoprost-Travatan                                       | 0.004%       | 2.5ml         | 165              | 66           | 2                          | 4.9          | 146.7          |
| Brimonidine-Alphagan                                      | 2%           | 5mls          | 84               | 17           | 4                          | 2.4          | 74.6           |
| Brinzolamide-Azopt                                        | 0.2%         | 5mls          | 132              | 26.4         | 6                          | 5.8          | 175.9          |